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Research Article
A role for trypanosomatid aldo-keto reductases in
methylglyoxal, prostaglandin and isoprostane
metabolism
Adam J. Roberts*, Joanne Dunne†, Paul Scullion, Suzanne Norval and Alan H. Fairlamb
Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Correspondence: Alan H. Fairlamb (a.h.fairlamb@dundee.ac.uk)
Trypanosomatid parasites are the infectious agents causing Chagas disease, visceral and
cutaneous leishmaniasis and human African trypanosomiasis. Recent work of others has
implicated an aldo-keto reductase (AKR) in the susceptibility and resistance of
Trypanosoma cruzi to benznidazole, a drug used to treat Chagas disease. Here, we show
that TcAKR and homologues in the related parasites Trypanosoma brucei and
Leishmania donovani do not reductively activate monocyclic (benznidazole, nifurtimox
and fexinidazole) or bicyclic nitro-drugs such as PA-824. Rather, these enzymes metabol-
ise a variety of toxic ketoaldehydes, such as glyoxal and methylglyoxal, suggesting a role
in cellular defence against chemical stress. UPLC-QToF/MS analysis of benznidazole
bioactivation by T. cruzi cell lysates conﬁrms previous reports identifying numerous drug
metabolites, including a dihydro-dihydroxy intermediate that can dissociate to form
N-benzyl-2-guanidinoacetamide and glyoxal, a toxic DNA-glycating and cross-linking
agent. Thus, we propose that TcAKR contributes to benznidazole resistance by the
removal of toxic glyoxal. In addition, three of the four enzymes studied here display
activity as prostaglandin F2α synthases, despite the fact that there are no credible
cyclooxygenases in these parasites to account for formation of the precursor PGH2
from arachidonic acid. Our studies suggest that arachidonic acid is ﬁrst converted
non-enzymatically in parasite lysates to (PGH2-like) regioisomers by free radical-
mediated peroxidation and that AKRs convert these lipid peroxides into isoprostanes,
including prostaglandin F2α and 8-iso-prostaglandin F2α.
Introduction
Parasitic protozoa belonging to the order Kinetoplastida cause three neglected tropical diseases,
Chagas disease, human African trypanosomiasis and leishmaniasis due to infection with Trypanosoma
cruzi, Trypanosoma brucei and Leishmania spp., respectively, see review [1]. The burden of these
three ‘neglected’ tropical diseases is almost exclusively associated with poverty and therefore there has
been little incentive for pharmaceutical companies to invest in developing new treatments, see review
[2]. Currently, the nitro-drugs benznidazole and nifurtimox developed over 40 years ago are the only
therapies available for the treatment of Chagas disease, with nifurtimox also constituting part of the
combination therapy ‘NECT’ for late-stage human African trypanosomiasis [3]. In addition, another
nitro-drug, fexinidazole, has shown activity against all three parasites [4–6] and consequentially is
now under clinical assessment for all three diseases.
The anti-parasitic activities of these nitro-containing pro-drugs are dependent upon parasite-
facilitated bio-activation by a bacterial-like type I nitroreductase NTR1 [7] to form toxic reactive inter-
mediates [8–10], and consequently, loss of NTR1 is a key resistance determinant [11,12]. Notably,
other enzymes have been implicated in resistance to benznidazole in T. cruzi, the FMN containing
‘old yellow enzyme’ a functional prostaglandin F2α synthase [13,14] and an aldo-keto reductase (AKR)
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[15]. Somewhat paradoxically, the latter enzyme has been reported to activate benznidazole, yet overexpression
of AKR in T. cruzi decreased rather than increased susceptibility to benznidazole [16]. Members of this AKR
superfamily, characterised by their ability to reduce aldehydes and/or ketones, have been identiﬁed in all
domains of life [17]. The activity of these enzymes requires either NADH and/or NADPH to reduce a variety
of substrates, including, but not limited to aldoses, steroids, methylglyoxal [18] or prostaglandins [19]. In the
trypanosomatid parasites Leishmania spp. and T. brucei, the production of prostaglandin F2α has been reported
to be catalysed by a member of the AKR family [19,20]; however, the equivalent enzyme in T. cruzi is reported
not to catalyse this reaction [21]. Given the conﬂicting and contradictory reports in the literature, we have
re-examined the ability of TcAKR to metabolise benznidazole and carried out a comparative enzymological
study of trypanosomatid AKRs to elucidate their potential metabolic roles in prostanoid and glyoxal
metabolism.
Experimental procedures
Cloning and expression of recombinant proteins
The open reading frames (ORFs) encoding LiPGFS1 (LinJ.32.0470, http://tritrypdb.org) and HsPGFS
(NP_003730.4) were synthesised by GeneART™. The ORFs of TcAKR (GenBank MH593394), TbPGFS
(Tb927.11.4700) and LiPGF2 (LinJ.31.2210) were ampliﬁed from genomic DNA isolated from T. cruzi Silvio
X10/7 clone A1, T. brucei 427 and Leishmania infantum genomic DNA, respectively, using primers (Table 1)
and pfu polymerase. The resulting PCR products were cloned into TOPO zero blunt. The ORFs of each
gene were digested with the appropriate restriction endonucleases and ligated into pET15b-TEV, yield-
ing pET15b-TEV-HsPGFS, pET15b-TEV-TcAKR, pET15b-TEV-LiPGFS1, pET15b-TEV-LiPGFS2 and
pET15b-TEV-LiAKR. All plasmids were sequenced (www.dnaseq.co.uk) to verify the correct sequences.
Plasmids were transformed into Rosetta (DE3) pLysS and 10-ml cultures were used to inoculate 1 l of
Autoinduction medium [22] with shaking at 30°C for 12 h. Cells were harvested by centrifugation (5090×g for
30 min at 4°C) and resuspended in buffer A (25 mM sodium phosphate buffer, 300 mM NaCl and 25 mM
imidazole, pH 8.0) supplemented with DNase I, lysozyme and complete EDTA-free protease inhibitor cocktail
tablets (Roche). Cells were lysed at 30 kPsi using a continuous ﬂow cell disruptor (Constant systems) and
soluble proteins obtained by centrifugation (20 000×g, 30 min and 4°C). The soluble fraction was loaded onto a
5-ml HisTrap HP column and the bound protein eluted with a gradient of imidazole (0–250 mM) in buffer
A. Fractions containing the protein of interest were pooled and the hexahistidine tag was removed with TEV
protease overnight at 4°C while dialysing against 25 mM sodium phosphate, 300 mM NaCl, pH 8.0, in a 10 000
MWCO membrane. Pure protein was observed after a ﬁnal HisTrap HP puriﬁcation step.
Oligomeric structure
Recombinant proteins were loaded onto a Superdex 75 10/300 or Superose 12 10/300 column, equilibrated in
25 mM HEPES, 150 mM NaCl, pH 7.33 and the elution volume of the recombinant proteins was compared with
Table 1 List of primers used in the present study
Primer Sequence
TcAKR-F catATGAATTGCAATTACAACTGTGTGACACTCC
TcAKR-R ggatccTCACTCCTCTCCACCAGGG
TbPGFS-F catATGGCTCTCACTCAATCCCTAAAACTC
TbPGFS-R ggatccTCAAAAGTCGTTCATGAAGACCTCC
LiPGFS2-F aaaacatATGGCTGACGTTGGTAAGGCAATGG
LiPGFS2-R ttttggatccTTAGAACTGCGCCTCATCGGGGTC
TcPGF2α-F catATGGCGACGTTCCCCGAAC
TcPGF2α-R ggatccTTAGTTGTTGTACGTCGGGTAATCG
Restriction sites are underlined.
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that of known protein standards (Bio-Rad). TcAKR separations were also repeated using the Superose 12 10/300
column with the high salt buffer (150 mM Tris–HCl, pH 7.6, 300 mM NaCl) as previously described [21].
Enzyme assays
Enzymatic activity was assessed by measuring the continuous oxidation of NADPH at 340 nm in the presence
of varying concentrations of substrate using a Shimadzu UV-2401 or 1601 spectrophotometer. Measurements
were taken under steady-state conditions, with a ﬁxed concentration of NADPH (100 mM) in 25 mM HEPES,
150 mM NaCl, pH 7.33, using an appropriate amount of enzyme. Enzyme concentrations for measuring the
speciﬁc activities were quantiﬁed with the Bradford protein assay using bovine serum albumin as standard.
Enzyme concentration for kinetic characterisation was determined by UV spectroscopy using the molar extinc-
tion coefﬁcients of 37 735 for HsPGFS, 60 470 for TcAKR, 51 590 for TbPGFS, 52 930 for LiPGFS1 and 51 530
for LiPGFS2 calculated using CLC workbench version 6.9.1. The observed rate of change at 340 nm was con-
verted into s−1 prior to ﬁtting the data to the Michaelis–Menten kinetics equation in GraFit 5.0 yielding appar-
ent values for kcat and Km. Reported values for Km (Kappm ) and kcat values are the weighted mean of
independent experiments. Weighted means and standard deviations were calculated using the following equa-
tions [23], where A, B…I are the means and a, b…i are standard deviations of A, B, etc.
Weighted mean of individual mean values
¼ (A=a
2)þ (B=b2)þ . . .þ (I=i2)
(1=a2)þ (1=b2)þ . . .þ (1=i2)
Weighted mean of standard deviations
¼ (1=a)þ (1=b)þ . . .þ (1=i)
(1=a2)þ (1=b2)þ . . .þ (1=i2)
Recombinant prostaglandin F2α synthase assay
A total of 1 mg of puriﬁed proteins (TcAKR, LiPGFS1, LiPGFS2, TbPGFS, HsPGFS and TcOYE) were incu-
bated in the enzyme assay buffer in the presence of 10 mM prostaglandin H2 (Cayman Chemicals) and
100 mM NADPH for 1 h at 37°C. Samples were inactivated by the addition of two volumes of acetonitrile and
analysed by LC–MS/MS as described below for the analysis of arachidonic acid and a prostaglandin standard
mixture (Cayman Chemicals).
UPLC-QToF/MS analysis of benznidazole metabolism
Recombinant TcAKR (13 mg and 130 mg ml−1) was incubated with 100 mM benznidazole and 100 mM
NADPH for 1 h at 37°C in 25 mM HEPES, 150 mM NaCl, pH 7.33. Hypotonic lysates (40 mg) made from
T. cruzi wild-type or NTR1-overexpressing epimastigotes were incubated with 100 mM benznidazole and
1 mM NADH as described above as a positive control. Reactions with pure enzyme or crude parasite lysates
were terminated by the addition of two volumes of acetonitrile and analysed by UPLC-QToF/MS. Metabolite
identiﬁcation samples were analysed on a Waters Acquity UPLC coupled to a Waters Xevo QToF mass spec-
trometer. Chromatographic separation was achieved on a Waters BEH C18 column (50 × 2.1 mm, 1.7 mm
particle size) eluted with A: water + 0.1% formic acid, B: acetonitrile + 0.1% formic acid. A ﬂow rate of 0.5 ml min−1
and an injection volume of 5 ml were selected. Analysis was performed with a 7 min LC run: 98% A initially,
to 65% A after 4 min then 5% A after 5 min, held for 0.99 min before returning to 98% A after 6 min. MSE
spectra were acquired, allowing exact mass precursor and fragment data to be simultaneously collected over a
mass range of 50–1200 m/z with the following mass spectrometer parameters: positive electrospray ionisa-
tion, cone voltage 38 V, mass range 100–1200 m/z, ramping collision energy 20–40 V, capillary voltage
1.5 kV, desolvation temperature 500°C, source temperature 120°C, desolvation gas (nitrogen) 800 l h−1 and
cone gas (nitrogen) 10 l h−1.
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Parasite growth and electroporation
Epimastigotes of the T. cruzi strain Silvio X10/7 (MHOM/BR/78/Silvio; clone X10/7) clone A1 were grown
RTH/FCS medium at 28°C [24]. T. brucei bloodstream-form parasites were grown in an HMI9-T [25] medium
at 37°C and Leishmania donovani (MHOM/SD/62/1S-CL2D) promastigotes were grown in a modiﬁed M199
medium described previously [26]. Transgenic parasites overexpressing NTR1 (TCSYLVIO_001958) were gen-
erated by transfection of plasmid pTREX-TcNTR1 with an Amaxa Nucleofector 2b device using program
U-33. Transgenic parasites were selected by the addition of G418 at 250 mg ml−1.
Arachidonic acid co-culture experiment
T. brucei bloodstream-form parasites, Leishmania donovani promastigotes and T. cruzi epimastigotes, were incu-
bated in the presence of 66 mM arachidonic acid (Sigma–Aldrich) for 16 h at 37°C, 28°C and 28°C, respectively.
Parasites were collected by centrifugation and washed in PBS three times prior to biological inactivation by three
rounds of freeze–thaw before mixing with two volumes of acetonitrile and analysis by LC–MS/MS.
Lysate arachidonic acid experiment
T. cruzi epimastigotes and T. brucei BSF were harvested by centrifugation at 800×g and washed three times in ice
cold PBS. Parasites (1 × 108) were collected and lysed by hypotonic lysis (10 mM Tris–HCl, pH 7.5) for 5 min on
ice. Incubations with and without 1 mM arachidonic acid were carried as previously described [19], in a reaction
volume of 400 ml and reactions terminated by the addition of 800 ml acetonitrile. Samples were subjected to three
rounds of freeze–thaw treatment to ensure biological inactivation, prior to analysis by LC–MS/MS. All samples
were analysed on a Waters TQ-S with Acquity UPLC using a Waters BEH C18 column (50 × 2 mm, 1.7 mm par-
ticle size). Source temperature was 150°C and desolvation gas temperature was 600°C. Eluents used were A: water
+ 0.01% formic acid, B: acetonitrile + 0.01% formic acid and the ﬂow rate was 0.5 ml min−1. Initial work on the
incubation of arachidonic acid with parasites was performed with a 6 min LC run: 95% A initially, to 80% A after
1 min then 60% A after 4 min, to 5% A after 4.5 min, held for 0.5 min before returning to 95% A after 5.1 min.
Further work on the incubation of arachidonic acid with cell lysates was performed with a 10 min LC run: 95% A
initially, to 80% A after 1 min then 60% A after 8 min, to 5% A after 8.1 min, held for 0.9 min before returning
to 95% A after 9.1 min. Multiple reaction monitoring (MRM) transitions used for the prostaglandin species
monitored are listed in Table 2 and Supplementary Figure S1 (all in negative ion mode).
Results
Characterisation of TcAKR
The enzymatic function of TcAKR is far from clear: it is annotated as a prostaglandin F synthase in some
genomic databases, yet the recombinant protein is reported to lack such activity [21] and other possible physio-
logical substrates have not been tested. It has also been proposed that TcAKR plays a role in the metabolism of,
and resistance to, benznidazole [15,16]. To clarify these issues, TcAKR was expressed in Escherichia coli, puri-
ﬁed to homogeneity (Figure 1A) and its physico-chemical properties were determined. The puriﬁed protein
(with or without the His6-tag) was analysed by size exclusion chromatography and found to elute as a single
symmetrical peak with a calculated Mr close to that of a theoretical monomer (Figure 1B), when separated
Table 2 MRM transitions used for detecting the prostaglandin
species and their retention times
Chromatograms of the 10 min chromatographic separations are
provided in Supplementary Figure S1.
Prostaglandin MRM transition Retention time (min)
6-keto PGF1α 369.2 > 163.1 3.09
Iso-PGF2α 353.0 > 192.9 4.25
PGF2α 353.0 > 192.9 4.88
PGF1α 355.2 > 311.2 4.96
PGE2 351.1 > 271.1 5.06
PGE1 353.2 > 317.2 5.31
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under quasi-physiological conditions (pH 7.33, 150 mM NaCl). This ﬁnding is in complete contrast with that
of a previous study by Garavaglia et al. [21], who reported the presence of mixed species containing mono-
meric, dimeric and tetrameric forms of the enzyme from the CL-Brener strain of T. cruzi. When repeating
these authors’ conditions using the same column and buffer conditions, the TcAKR isolated from our labora-
tory strain of T. cruzi continued to elute as a monomeric species, irrespective of the amount loaded
(Figure 1C). The reason for this discrepancy is not clear. Both enzymes are highly similar (97% amino acid
sequence identity); however, modelling onto the published crystal structure of this enzyme [27] suggests that
the majority of these differences are located on the surface. Notably, one allele in the CL-Brener strain contains
an additional cysteine (Y51C) (SNP: NGS_SNP.TcChr40-P.486408), which is absent in the Silvio X10-7 clone
used in our study. Modelling on the TcAKR crystal structure 4GIE [27] suggests that this cysteine residue is
likely to be solvent accessible and therefore available for disulﬁde formation with another monomer. This could
account for dimer (but not the tetramer) species reported by Garavaglia et al. [21] and would explain why their
dimeric species did not dissociate into monomers during mass spectrometry.
Substrate-speciﬁcity of TcAKR
As TcAKR has no clear biological role, a BLAST analysis was carried out in an attempt to assign a possible
function for this enzyme, identifying enzymes in vitamin K biosynthesis, glyoxal metabolism and synthesis of
prostaglandin F2α. The activity of TcAKR was assessed with a ﬁxed concentration of a variety of biologically
relevant or typical AKR substrates (Table 3) identifying methylglyoxal, a toxic by-product of glycolysis, to have
one of the highest speciﬁc activities with the puriﬁed enzyme. Subsequent characterisation of glyoxal and
A
C
B
Figure 1. Characterisation of recombinant TcAKR.
(A) Purity of recombinant enzyme by SDS–PAGE: insoluble (lane 1), soluble (lane 2), pooled fraction after HisTrap (lane 3) and
pooled protein after hexahistidine tag removal (lane 4). (B) Elution proﬁle of recombinant TcAKR (black) and His6-TcAKR (blue)
under quasi-physiological conditions from a Superdex 75 10/300 column. (Inset) Elution volumes of known protein standards
(open circles) plotted against the log10 of their molecular masses. Theoretical elution volume of the T. cruzi AKR monomer
(closed circle). Linear ﬁt R2: 0.998. (C) Elution proﬁle of recombinant TcAKR at 2 mg ml−1 (black) and 20 mg ml−1 (blue) under
quasi-physiological conditions from a Superose12 10/300 column.
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methylglyoxal showed them to follow Michaelis–Menten kinetics (Figure 2A,B). Notably, methylglyoxal had a
Km of 0.24 mM and kcat/Km (1.95 × 10
4 M s−1) which is similar to that of SakRI (1.1 × 104 M−1 s−1), a cyano-
bacterial enzyme involved in methylglyoxal detoxiﬁcation [18].
A B
C D
Figure 2. Testing benznidazole as a substrate or inhibitor of recombinant TcAKR.
(A) Benznidazole as a substrate of TcAKR, DMSO (open circles), 60 mM benznidazole (closed circles), 60 mM phenylglyoxal
(open squares). (B) Inhibition of phenylglyoxal (60 mM) metabolism by benznidazole, DMSO (closed circles), 60 mM
benznidazole (open circles). (C and D) Michaelis–Menten plots of activity with glyoxal and methylglyoxal, respectively.
Table 3 A survey of purified recombinant trypanosomatid aldo-keto reductases with
various substrates
Compounds (60 mM) were assayed spectrophotometrically in the presence of 100 mM NADPH.
Specific activity is given in mmol min−1 mg−1. Values are the means and standard deviations (n = 3).
Substrate TcAKR LiPGFS1 LiPGFS2 TbPGFS
2-Nitrobenzaldehyde 0.20 ± 0.004 1.40 ± 0.04 2.51 ± 0.029 0.73 ± 0.017
3-Nitrobenzaldehyde 0.16 ± 0.003 0.06 ± 0.002 2.40 ± 0.037 1.86 ± 0.009
4-Nitrobenzaldehyde 0.39 ± 0.009 0.06 ± 0.002 2.49 ± 0.142 0.71 ± 0.013
Glyoxal 0.001 ± 0.001 0.02 ± 0.001 0.09 ± 0.001 0.15 ± 0.005
Methylglyoxal 1.20 ± 0.022 0.61 ± 0.02 1.79 ± 0.009 0.67 ± 0.012
Phenylglyoxal 3.66 ± 0.092 3.11 ± 0.018 2.46 ± 0.084 0.78 ± 0.037
Vitamin K3 epoxide N.A. N.A. N.D. N.A.
Glyceraldehyde 0.05 ± 0.005 N.D. 0.16 ± 0.002 0.13 ± 0.004
Benznidazole N.A. N.A. N.A. N.A.
Abbreviations: NA, not active; ND, not determined.
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).2598
Biochemical Journal (2018) 475 2593–2610
https://doi.org/10.1042/BCJ20180232
Although benznidazole was recently reported to be a substrate of this enzyme (73 mU mg−1) [16], we were
unable to detect any increase in NADPH oxidation above the background rate (1 mU mg−1) when benznidazole
was present at 60 mM (Figure 2C). Neither did we observe any inhibition of enzymatic activity by benznidazole
with phenylglyoxal as a substrate (Figure 2D). To conﬁrm our negative ﬁndings with the spectrophotometric
assay, the puriﬁed enzyme was incubated with NADPH in the presence or absence of benznidazole for 1 h at
37°C and subsequently analysed by UPLC-QToF/MS. Even in the presence of excess enzyme (130 mg ml−1), we
were unable to detect any utilisation of benznidazole (Figure 3A,B). In contrast, incubation of benznidazole
with parasite lysates under identical conditions converted more than half of the benznidazole (Figure 3C,D)
into multiple metabolites already reported in the literature (Table 4) [8,10]. The smaller peak size of benznida-
zole incubated with the lysate prepared from NTR-overexpressing parasites (Figure 3D) is consistent with
NTR-activating benznidazole [8]. Other clinically pertinent nitro-drugs for the trypanosomatid parasites, nifur-
timox, fexinidazole [5] and (R)-PA824 [28] were also not substrates for AKR. These results demonstrate that
TcAKR is not directly involved with the bio-activation of benznidazole or other nitro-drugs.
Identifying alternative methylglyoxal-reducing enzymes in the trypanosomatids
Homologues of TcAKR were identiﬁed in the related parasites T. brucei and L. infantum, identifying one and
two homologues, respectively. The identiﬁcation of a T. brucei homologue was of particular interest as this
parasite notably lacks the trypanothione-dependent glyoxalase pathway present in Leishmania and T. cruzi
[29]. The genes encoding these enzymes have been annotated as prostaglandin F synthases, with the L. infan-
tum (LinJ.31.2210) and T. brucei (Tb927.11.4700) sequences previously assigned to AKR sub-family 5A [17].
Alignments revealed the trypanosomatid sequences to share between 54 and 57% identity with each other
(Figure 4) with all maintaining the conserved AKR catalytic tetrad identiﬁed in T. brucei [30]. To further char-
acterise the enzymatic properties of these proteins, the homologues identiﬁed from T. brucei and L. infantum
were overexpressed in E. coli and puriﬁed to homogeneity using the same two-stage puriﬁcation as for TcAKR
(Figure 5A). The typical yields of pure protein ranged between 10 and 30 mg l−1 of starting culture. Similar to
TcAKR, the homologues TbPGFS, LiPGFS1 and LiPGFS2 were primarily monomeric (Figure 5B–D) when ana-
lysed by size exclusion chromatography under the same quasi-physiological conditions. However, when
LiPGFS1 was incubated for 96 h at 4°C in the absence of a reducing agent, 25% of the protein eluted with an
apparent mass of a dimer (Figure 5E). The addition of a reducing agent completely abolished the dimeric
species (Figure 5E), indicating the dimeric form to be reliant upon disulﬁde bond formation.
Figure 3. Metabolism of benznidazole by TcAKR and whole cell lysates of T. cruzi.
Extracted ion chromatograms measuring the relative amount of benznidazole in the presence of NADH plus (A) no enzyme, (B)
0.13 mg ml−1 recombinant TcAKR, (C) 40 mg ml−1 of a wild-type T. cruzi lysate and (D) 40 mg ml−1 of a lysate-overexpressing
NTR.
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Comparative kinetics of trypanosomatid AKRs
The enzymatic properties of the three additional puriﬁed homologues were assessed with the same substrates
tested against TcAKR, ﬁnding that all of the trypanosomatid enzymes were capable of using the same substrates
(Table 3). Similar to TcAKR, neither the Leishmania nor T. brucei enzymes were capable of using the nitro-
drugs benznidazole or nifurtimox as substrates. As the homologues displayed identical substrate usage, the
basic kinetic parameters of each enzyme for each of the substrates were determined at a ﬁxed concentration of
NADPH (Table 5). Comparing the apparent Kappm values, substrate turnover rates and catalytic efﬁciencies of
the enzymes revealed LiPGFS1 to be more kinetically similar to the TcAKR than TbPGFS, with the opposite
relationship true of LiPGFS2 suggesting a divergence in AKR evolution in Leishmania. We observed the cata-
lytic efﬁciency (kcat/Km) of methylglyoxal as a substrate of these enzymes to be relatively unchanged despite up
to 20- and 80-fold differences kcat and Km values, respectively. This trend also was observed for glyoxal, phenyl-
glyoxal and D,L-glyceraldehyde. However, the nitro-aromatic compounds were much more efﬁciently utilised in
the case of TbPGFS or LiPGFS2 compared with LiPGFS1 and TcAKR. LiPGFS2 used in our study appears to
be the same as a glutathione-speciﬁc aldose reductase [31]; however, it appears that glutathione is not required
for the functional activity of this enzyme in our hands. The human prostaglandin F2α synthase (NP_003730.4)
also displayed trace activity with methylglyoxal as a substrate, but with a much lower efﬁciency (∼10 M−1 s−1),
indicating that it is unlikely to be a functional mechanism for detoxiﬁcation of methylglyoxal in human cells.
Arachidonic acid and prostaglandins
Previous studies on these enzymes have suggested that the T. brucei and Leishmania spp. AKRs function as
prostaglandin F2α synthases in these parasites, converting prostaglandin H2 (PGH2) to the F2α form. While our
observations for prostaglandin F2α synthase activity of TbPGFS and LiPGFS2 were in agreement with the litera-
ture [19,20], we also observed PGF2α activity for LiPGFS1 (Table 6). We also conﬁrm the lack of prostaglandin
F2α synthase activity of TcAKR as reported by Garavaglia et al. [21].
Table 4 Benznidazole-derived metabolites
Metabolites were identified by accurate mass and presence in the sample, but absence in the control incubations.
Retention time
(min) Structure
Metabolite
number1
[M
+H]+
Ionisation
state
WT
lysate
NTROE Lys
B Control TcAKR
3.1 Benznidazole NA 261.10 1 NA NA NA NA
1.59 Hydroxylamine or hydroxy derivative 1 or 2 11 or 19 247.11 1 Y Y N N
1.8 Amino derivative of benznidazole 1 231.12 1 Y Y N N
1.49/1.59 Dihydroxy-dihydro derivative 3 265.13 1 Y Y N N
1.59 N-benzyl-2-guanidinoacetamide 5 207.13 1 N Y N N
1.3 2-Amino-N-benzylacetamide 22 165.10 1 Y Y N N
1.74 Amino derivative + glutathione (isomer 1) 7 or 8 536.19 1 Y Y N N
268.56 2 Y Y N N
1.83 Amino derivative + glutathione (isomer 2) 7 or 8 536.19 1 Y Y N N
268.56 2 Y Y N N
1.55/1.64 Amino derivative + glutathione + H2O 4 554.20 1 Y Y N N
277.60 2 Y Y N N
1.76/1.93/2.31 Amino derivative + cysteine 9 350.13 1 Y Y NN NN
1.34 Amino derivative + ovothiol A 12 or 14 430.17 1 Y Y N N
215.58 2 Y Y N N
3.8 Possible benznidazole adduct 26 385.18 1 Y Y N N
1.63 Possible benznidazole adduct 28 368.12 1 N Y N N
3.64/3.8 Possible benznidazole adduct NA 614.35 1 Y Y N N
2.13 Possible benznidazole metabolite NA 204.05 1 Y Y N N
Abbreviations: NA, not applicable.
1The metabolite numbers refer to the metabolite list in Trochine et al. [10].
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Observations that these parasites are capable of synthesising PGH2 from arachidonic acid currently do not ﬁt
with the known prostaglandin biosynthetic pathway due to the absence of cyclooxygenases 1 and 2 that catalyse
the conversion of arachidonic acid to PGH2. Our alternative hypothesis is that the formation of the prostaglan-
dins from arachidonic acid could be due to the formation of structurally similar isomers, the isoprostanes.
These molecules have been reported as a marker of oxidative stress [34] and are formed by the free radical-
mediated peroxidation of arachidonic acid within the cell [35]. In contrast with enzyme-mediated peroxidation
that typically generates a single enantiomer of a single regioisomer, non-enzymatic peroxidation generates
racemic mixtures with multiple regio- and stereo-centres [36,37]. Among other products, non-enzymatic perox-
idation of arachidonic acid produces four F2-isoprostane regioisomers (Figure 6), each of which comprises
eight racemic diastereomers, making 64 in total [38]. Prostaglandin F2α and its isoprostane 8-isoprostane F2α
(15-F2t-IsoP or iPF2α-III) belong to the 15-series regioisomers, which, together with the 5-series, are formed in
greater amounts than the less stable 8- and 12-series [38]. Although the four F2-isoprostane classes are isobaric
(m/z 353), they can be distinguished by their MRM spectra which yield different fragmentation patterns below
m/z 200, with the 15-series (iPF2α-III series) producing a predominant 193 anion [39]. The 5-series produces a
minor peak at 193, but can be distinguished by its predominant MRM product at m/z 115 and different reten-
tion time on HPLC. To determine if prostaglandins or isoprostanes could be produced, parasites were
co-incubated with arachidonic acid and analysed by LC–MS/MS and compared with known analytical stan-
dards. Despite the high sensitivity of the LC–MS/MS assay (LOD of ∼0.1 ng ml−1 for both species) our initial
experiments, where 66 mM arachidonic acid was co-incubated with intact parasites, failed to detect either pros-
taglandin F2α or its isoprostane 8-isoprostane F2α. However, the addition of 1 mM arachidonic acid to hypo-
tonic lysates of T. brucei or T. cruzi led to the production of multiple isomeric peaks on the MRM channel for
MTRQKNELMK TRQLG - - - - - - - - - - QSAVQ I T P I I LGTWQ AGKRNWAD I D DQE I VAG I RA AVDAG I T T I D
MNCNYSC - - - - - - - - - - - - - - - V T LHNSAQ MPQLGLGVWR AQ - - - - - - - D GAE TANAVRW A I EAGYRH I D
MADVGKAM - - - - - - - - - - - - - - V T L SNGVQ MPQLGLGVWQ SP - - - - - - - A GEV TANAVKW ALCAGYRH I D
M - - TGKCTH - - - - - - - - - - - - - V T LGNGVQ VPQLG I GTWE AK - - - - - - - N GNEVVQN I KW A I NAGYRH I D
MAL TQS - - - - - - - - - - - - - - - - LKL SNGVM MPVLGFGMWK LQ - - - - - - - D GNEAE TATMW A I KSGYRH I D
TAE I YGD - - - - GDSERRVAE A I APQRDQVT L L TKV FANHL HHDQV I - TAC ENS LNRLQTD Y I DL YQ I HWP
TAY FYNNEKG VGQG I R - - - E SG - VPREEVW VT TKVWNSDL GYEKT L - AAF ERSRE L LGLE Y I DL Y L I HWP
TAA I YKNEES VGAGLR - - - A SG - VPREDV F I T TKLWNTEQ GYES T L - AAF EESRQKLGVD Y I DL Y L I HWP
TAHYYKNEKG VGQG I S - - - E CG - VPRSD I F V T TKLWNYDH GYESAL - AAF EQSRQALGVE YVDLY L I HWP
TAA I YKNEES AGRA I A - - - S CG - VPREE L F V T TKLWNSDQ GYES T L - SAF EKS I KKLGLE YVDLY L I HWP
AGTWNS - - - - - - - - - - - - - - - - - - - - - DL V P I AE TMAALN QLKEQGK I RA I GVSNFS LAQ LQEAMEHGQ I
- - - GK - - - - - - - - KKF VD - - - - - - - - - - - - - - T - -WKALE KLYEEKKVRA I GVSNFEPHH - - - L T E - - - -
R - - GKD I V - S KEGKKYLD - - - - - - - - - - - - - - S - -WRAFE QLYKDKKVRA I GVSNFH I HH - - - L ED - - - -
- - - GPN - - - - - - - RSY I E - - - - - - - - - - - - - - T - -WRAFE KLYEMKKVRA I GVSNFEPHH - - - LDD - - - -
- - - GKD - - - - - - - - KF I D - - - - - - - - - - - - - - T - -WKAFE KLYADKKVRA I GVSNFHEHH - - - I EE - - - -
D - - - - - - S I Q PPY - - - - S L F WRA I ERE I QP FCAAQQ I S I L AYSS LAQGL L TGKFGPDHQF AAGDHRSHNR
- - L FKSCK I - RP L VNQVE LH P L FQQRALRE FCKQHN I AV T AWSPLGSG - - - - - - - - - - - - DR - - - - - - TG
- - V LAMCTV - T PMVNQVE LH P LNNQAELRA FCDAKQ I KVE AWSPLGQG - - - - - - - - - - - - K - - - - - - - - -
- - L LANCTV - PPMVNQVEMH PHFQQKALRA YCAEKN I AV T AWRPLGKG - - - - - - - - - - - - A - - - - - - - - -
- - L LKHCKV - APMVNQ I E LH P L LNQKALCE YCKSKN I AV T AWSPLGQG - - - - - - - - - - - - H - - - - - - - - -
L YADPENYQR VQTALGL LKP I A - - T TKNCT LAQLA I AWL I RQPQTNA I VG ARNAQQA I AN AQA I - - - - - -
F LKNH - - - - - - - - - - - V LGE I AKK - - HNKS PAQVV I RWD I - QHG I V T I PK S TNKGR I QEN FNVW - - - - - D
L L SNP - - - - - - - - - - - I LAA I GAK - - YNKT AAQV I LRWN I - QKNL I T I PK SVHKER I EEN ADVF - - - - - N
L L T EP - - - - - - - - - - - QL VE LAEK - - HKRS AAQV I I RWL I - QLGV I A I PK SSHEER I KQN FDV F - - - - - D
L VEDA - - - - - - - - - - - RLKA I GGK - - YGKT AAQVMLRWE I - QAGV I T I PK SGNEAR I KEN GN I F - - - - - D
- - - - - - - DVE L TAKDLEA I D H I GRTV T - DP LDENP L LWN - - - - - W
- - - - - - - - FK L T EEEMRQ I D E LNEDKRFGG HPDNF F - - - - PGGEE
- - - - - - - - F E LGAEDVMR I D ALNTNSRYGP DPDEAQ - - - - - - - - F
- - - - - - - - F E L SPEDMRRLE SMDKNSR I GP SPE T F F - - - - P T ECK
- - - - - - - - F E L TAED I QV I D GMNAGHRYGP DPEV FM - - - - - NDF *
Figure 4. Sequence alignment of AKR homologues identiﬁed by BLAST.
Multiple sequence alignment of SakRI, TcAKR (TcCLB.511287.49), LiPGFS1 (LinJ.31.2210), LiPGFS2 (LinJ.32.0470) and
TbPGFS (Tb927.11.4700). The conserved AKR catalytic tetrad identiﬁed in T. brucei is marked by the red boxes. Blue boxes
indicate solvent accessible cysteine residues identiﬁed in the crystal structures of TbPGFS TcAKR and LiPGFS2 (PDB
accession numbers 1VBJ, 4GIE and 4G5D) [27]. Orange box highlighting Y51C allelic variation was observed in CL-Brener.
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Figure 5. Characterisation of LiPGFS1, LiPGFS2 and TbPGFS.
(A) SDS–PAGE showing puriﬁcation of TbPGFS1, LiPGFS1 and LiPGFS2 showing insoluble, soluble, pooled protein from
HisTrap column and protein with the hexahistidine tag removed. Size exclusion elution proﬁles of (B) TbPGFS, (C) LiPGFS1 and
(D) LiPGFS2. Samples were separated on a Superose 12 10/300 column in 25 mM HEPES, 150 mM NaCl, pH 7.33. (E)
LiPGFS1 stored in the absence of a reducing agent analysed by size exclusion chromatography in the absence (blue) and
presence (red) of 0.5 mM TCEP using a Superdex 75 10/300 column.
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PGF2α and iso-PGF2α (Figure 7). A clearly resolved peak was detected for iso-PGF2α, along with a shoulder
with the same retention time as PGF2α. The identity of the other peaks is not known, but is likely to include
the other racemic diastereoisomers in the 15-series (Figure 6). Similar results were obtained for both T. brucei
and T. cruzi.
Discussion
The primary aim of the present study was to assess the capability of TcAKR to reduce or bio-activate clinically
relevant monocyclic and bicyclic nitro-drugs that are either in clinical use or under development for the treat-
ment of Chagas disease. Garavaglia et al. [16] reported that recombinant TcAKR and native TcAKR puriﬁed
from T. cruzi epimastigotes were able to reduce benznidazole with speciﬁc activities of 0.091 and 0.073 U mg−1,
respectively. In complete contrast, we found no evidence for the reduction of benznidazole by TcAKR
Table 5 Kinetic characterisation of trypanosomatid recombinant aldo-keto reductases with various
substrates
Substrate Units TcAKR LiPGFS1 LiPGFS2 TbPGFS
Glyoxal
kcat s
−1 4.56 ± 0.05 7.31 ± 0.19 1.05 ± 0.02 ND
Kappm
1 mM 8.30 ± 0.31 36.1 ± 2.39 0.56 ± 0.05 ND
kcat=Kappm M
−1 s−1 549 202 1880 ND
Methylglyoxal
kcat s
−1 4.69 ± 0.03 8.72 ± 0.17 1.13 ± <0.01 0.38 ± 0.007
Kappm mM 0.24 ± <0.001 0.80 ± 0.07 0.02 ± <0.001 0.01 ± <0.001
kcat=Kappm M
−1 s−1 19 500 10 900 56 500 38 000
Phenylglyoxal
kcat s
−1 4.46 ± 0.08 10.4 ± 0.22 1.17 ± 0.02 0.34 ± 0.014
Kappm mM 0.05 ± 0.003 0.14 ± 0.008 0.01 ± 0.0009 0.005 ± 0.0008
kcat=Kappm M
−1 s−1 89 200 74 300 58 500 68 000
2-Nitrobenzaldehyde
kcat s
−1 2.25 ± 0.112 8.50 ± 0.21 1.04 ± 0.02 0.41 ± 0.002
Kappm mM 0.71 ± 0.08
2 0.32 ± 0.02 0.0024 ± 0.0003 0.003 ± 0.0003
kcat=Kappm M
−1 s−1 3170 26 600 433 000 140 000
3-Nitrobenzaldehyde
kcat s
−1 4.07 ± 0.17 1.28 ± 0.03 1.04 ± 0.02 0.34 ± 0.005
Kappm mM 2.20 ± 0.16 1.55 ± 0.06 0.002 ± 0.0003 0.002 ± 0.0001
kcat=Kappm M
−1 s−1 1850 830 520 000 170 000
4-Nitrobenzaldehyde
kcat s
−1 3.7 ± 0.15 0.48 ± 0.01 1.13 ± 0.052 0.43 ± 0.008
Kappm mM 68 ± 0.07 0.43 ± 0.026 0.004 ± 0.0006
2 0.0043 ± 0.0002
kcat=Kappm M
−1 s−1 5440 1 110 283 000 100 000
D,L-glyceraldehyde
kcat s
−1 4.94 ± 0.11 8.72 ± 0.112 2.46 ± 0.132 0.37 ± 0.009
Kappm mM 1.50 ± 0.17 2.87 ± 0.08
2 1.07 ± 0.152 0.07 ± 0.005
kcat=Kappm M
−1 s−1 3290 3040 2300 5290
Abbreviations: ND, not determined.
1Kappm values determined with 100 mM NADPH.
2Weighted mean of two individual replicates, all others are n≥ 3.
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(<0.001 U mg−1) (Table 3); neither could we detect metabolism of benznidazole by TcAKR using UPLC-QToF/
MS under conditions where extensive metabolism occurred in whole cell lysates (Figure 3 and Table 4). It is
unlikely that amino acid substitutions in these AKRs are responsible for the discrepancy, because the
CL-Brener and Silvio enzymes are 97% identical and molecular modelling shows that the active sites are identi-
cal. Differences in assay conditions could be a possible explanation: our assays were at pH 7.33 in HEPES
buffer, whereas Garavaglia et al. used Tris–HCl, pH 6.5—an inappropriate buffer system since the pKa for Tris
is 8.3. Notably, these authors reported difﬁculties in measuring catalytic activity because of non-enzymatic reac-
tion between benznidazole and NADPH cofactor under their experimental conditions. We did not encounter
any such problem when pure recombinant TcAKR was assayed under our conditions by spectrophotometry
(Figure 2) or by mass spectrometry (Table 4). We conclude that TcAKR is not involved in the bioactivation of
benznidazole, but instead we offer a potential role for TcAKR in resistance to benznidazole as discussed below.
Table 6 Identification of prostaglandin F2α synthase activity in
trypanosomatid aldo-keto reductases and old yellow enzyme
Enzyme
Peak area
PGF2α PGF1α PGE2 PGE1
No enzyme control 3185 176 250 984
HsPGFS 6415 187 319 537
TcAKR 4231 190 097 1161
LiPGFS1 33 807 536 156 739 393
LiPGFS2 38 285 467 149 112 273
TbPGFS 28 568 306 139 483 606
TcOYE 25 216 510 133 298 353
Enzymes were incubated with PGH2 as described in Experimental Procedures and
analysed by LC–MS. 6-Keto-PGF2α and iso-PGF2α were not detected. PGH2 is
unstable and in the absence of enzyme is spontaneously rearranged to PGE2
[32,33].
Figure 6. Formation of F2-isoprostanes from arachidonic acid.
Abbreviations: IsoP, isoprostane.
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A second aim of our study was to elucidate the possible metabolic functions of these AKR homologues
across the Trypanosomatidae. All four enzymes across three representative species possess activity with ketoal-
dehydes with speciﬁcity constants (kcat/Km) in the order phenylglyoxal > methylglyoxal > glyoxal. Notably, all
four enzymes had speciﬁcity constants for methylglyoxal (range 1.1–5.7 [×104] M s−1) that are similar to that
of SakRI (1.1 × 104 M−1 s−1), a bacterial enzyme that has been implicated in methylglyoxal metabolism [18].
The speciﬁcity constant for TbPGFS with methylglyoxal (3.8 × 104 M−1 s−1) is an order of magnitude lower
than that reported with PGH2 (7 × 10
5 M−1 s−1) [30], whereas the reverse is observed for LiPGFS2 with methyl-
glyoxal (5.7 × 104 M−1 s−1) preferred over PGH2 (8.8 × 10
3 M−1 s−1) [20]. As previously reported [21] and con-
ﬁrmed here, the T. cruzi enzyme lacks prostaglandin F synthase activity; this is provided instead by old yellow
enzyme [32], a protein that is absent in T. brucei and L. infantum. Given the broad spectrum of activity with
ketoaldehydes, aromatic aldehydes, erythroses (the present study) and quinones [16,19,40], these enzymes are
more like carbonyl reductases (EC 1.11.184) [41] than prostaglandin F synthases (EC 1.1.1.188). Of the
Figure 7. MRM chromatograms monitoring for PGF2α /Iso-PGF2α in T. cruzi cell lysates.
Elution proﬁle of 2 ng ml−1 standards of iso-PGF2α (A) and PDF2α (B). T. cruzi cell lysates incubated with (D) or without (C)
1 mM arachidonic acid.
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physiologically relevant substrates examined here, methylglyoxal is a more efﬁcient substrate for all of these
enzymes compared with D,L-glyceraldehyde or glyoxal. Enzymes typically operate in cells at substrate concentra-
tions near to or within 10-fold below their Km [42,43]. Although the concentration of methylglyoxal is not
known for these parasites, the Kappm values (0.01–0.8 mM) for methylglyoxal determined here are consistent
with physiological levels of free metabolite of <5 mM reported in other cells [44]. The Km values are thus con-
sistent with a role in defence against carbonyl stress and are at the lower range of Km values reported for broad
speciﬁcity methylglyoxal reductases from Aspergillus (1.43 and 15.4 mM) [45], Saccharomyces (5.9 mM) [46],
Kluyveromyces (0.43 and 1.6 mM) [47] and Synechococcus sp. (0.08 mM) [18].
Our results suggest an important biological role in the detoxiﬁcation of toxic ketoaldehydes typiﬁed by
methylglyoxal, formed as a by-product of the glycolytic pathway, as well as from threonine degradation and
from lipid peroxidation [48,49]. Our previous studies have identiﬁed two pathways for degradation of methyl-
glyoxal in trypanosomatids, either by conversion to D-lactate catalysed by trypanothione-dependent glyoxalases
GLO1 and GLO2, or by conversion to L-lactate via methylglyoxal reductase and lactaldehyde dehydrogenase
[25]. Methylglyoxal is formed mainly from triose phosphate intermediates in glycolysis, a pathway whose ﬁrst
nine steps, including isomerisation of dihydroxyacetone phosphate and glyceraldehyde 3-phosphate, take place
in a peroxisome-like organelle, the glycosome [50]. It is of interest to note that PGFS and GLO2 are present in
highly puriﬁed glycosomal preparations from T. brucei [51] and, likewise, PGFS, GLO1 and two putative
D-lactate dehydrogenases are found in L. donovani glycosomes [52], suggesting a role for both pathways in pro-
tection against protein glycation [48] in these organelles as well as in the cytosol. Curiously, bloodstream forms
of T. brucei have the highest glycolytic ﬂux of all these trypanosomatids [53], yet lack GLO1 of the
trypanothione-dependent glyoxalase pathway present in Leishmania spp. and T. cruzi [25].
In the case of TcAKR, overexpression of this enzyme confers a modest resistance to benznidazole [16].
Benznidazole is a prodrug and undergoes activation via two sequential two-electron reduction steps by a mito-
chondrial nitroreductase to form a toxic reactive hydroxylamine intermediate (Figure 8). This compound subse-
quently forms adducts with low molecular mass thiols [10] or undergoes rearrangement to a
Figure 8. Possible role of AKR in the metabolism of benznidazole.
The metabolites shaded in grey were identiﬁed in our study (Table 4). The removal of glyoxal by AKR promotes further
metabolism to 2-amino-N-benzyl acetamide.
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dihydro-dihydroxy intermediate [8] that can dissociate to form glyoxal and N-benzyl-2-guanidinoacetamide
[54] (Figure 8). Glyoxal is toxic and mutagenic and reacts with DNA to form a cyclic glyoxal-deoxyguanosine
adduct, as well as causing deamination of deoxycytidine and cross-linking in DNA [55]. Thus, overexpression
of TcAKR may contribute to benznidazole resistance by facilitating removal of glyoxal.
Given the absence of genetic and biochemical evidence for cyclooxygenase-dependent synthesis of PGH2
from arachidonic acid [19,20,32], the evidence for speciﬁc prostaglandin metabolism requires critical reassess-
ment. In mammalian tissues, non-cyclooxygenase-derived F2-isoprostanes can be formed in situ on arachi-
donic acid-containing phospholipids via lipid peroxidation and then released by the action of phospholipase
A2 [35]. Alternatively, they can be formed from free arachidonic acid in vitro [56]. Leishmania spp. are able
to synthesise arachidonic acid de novo [57], whereas T. cruzi and T. brucei are able to scavenge it from the
extracellular medium and incorporate it into lipid bodies [57–59]. All species contain phospholipase A2
[60,61]. Our ﬁndings support the non-enzymatic formation of PGH2 and other F-type isoprostanes by free
radical peroxidation of arachidonic acid. Notably, the formation of multiple isobaric products (m/z 353) with
the characteristic MRM signal for the 15-series of F-type prostanoids (m/z 193) supports a non-enzymatic
peroxidation mechanism, in contrast with a cyclooxygenase-catalysed peroxidation that would generate a
single enantiomerically pure product [36,37]. In this respect, it is worth noting that the four studies reporting
enzymatic conversion of arachidonic acid into PGD2, PGE2 and PGF2α utilised an analytical approach that
focuses exclusively on these prostanoids [19,32,40,59] and predates the discovery of isoprostanes. The method
involves incubation of whole cell lysates with saturating amounts of arachidonic acid, spiking with trace
amounts of radiolabelled PGD2, PGE2 and PGF2α, separation by HPLC and quantitation of radiolabelled
peaks by enzyme immunoassay [62]. Thus, the large number of additional F2-isoprostane metabolites
observed here (Figure 7) may have been missed. We propose that arachidonic acid (free or as phospholipid)
undergoes non-enzymatic peroxidation to form 8-iso-PGH2 (among other enantiomers) which serves as
a substrate for AKRs to form 8-iso-PGF2α (and other isoprostanes). Additionally, we note that a report that
T. cruzi produces thromboxane A2 as well as PGF2α [63] could also involve a non-enzymatic pathway [64].
Thus, there is a need for a thorough re-evaluation of the nature of eicosanoids formed in these parasites and
the possible physiological role of the products. For example, it is worth noting that host immune responses to
parasite infection often involve oxidant stress [65,66] and that certain prostanoids formed via the free radical
route can have biological activity [67].
In conclusion, we have demonstrated that the substrate-speciﬁcity of these aldo-keto reductases is broader
than other prostaglandin F2α synthases and that they are likely to be involved in the elimination of certain
toxic ketoaldehyde metabolites derived from lipids, trioses and the drug, benznidazole.
Abbreviations
AKR, aldo-keto reductase; MRM, multiple reaction monitoring; NTR, nitroreductase; ORFs, open reading frames;
PGF2α, prostaglandin F2α; PGH2, prostaglandin H.
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